

moderna

NAIIS: Development of COVID-19 Vaccines Panel
 Mike Watson, MD, Consultant, Vaccines and Infectious Diseases, Moderna
 May 12, 2020

© 2020 Moderna Therapeutics

1

SARS-CoV-2 vaccine (mRNA-1273) – Experience with antigen
 Encoding full spike S protein (Class 1 viral fusion protein like RSV, HMPV, PIV, Flu, & Nipah)

© 2020 Moderna Therapeutics

2

mRNA vaccines – Understanding of mechanism of action
 Unique platform mechanism of action (MOA)

© 2020 Moderna Therapeutics

3

Platform – Significant experience in clinical studies.
 Summary body of data from mRNA vaccine candidates

Safety ≥1,500 healthy volunteers enrolled in ten Phase 1 and one Phase 2 vaccine trials (dose levels up to 400µg); emerging safety & tolerability profile consistent with marketed adjuvanted vaccines¹

Immunogenicity We have observed an ability to elicit neutralizing antibodies to viral antigens against all eight viruses, from clinical trial read outs to date

© 2020 Moderna Therapeutics

4

Uniform process allows for fast scale-up – Production experience
 High degree of flexibility

- Some LNP formulation
- Some mRNA nucleotides
- Some mRNA & LNP manufacturing processes

© 2020 Moderna Therapeutics


5

Accelerated research and development timeline
 SARS-CoV-2 (mRNA-1273)


IN 63 DAYS

© 2020 Moderna Therapeutics

6



7



8